Lead sponsor
Institute of Liver and Biliary Sciences, India
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
1
Active
90
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Not applicable
1
Trials by status
Not yet recruiting
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.HbA1c ≤10%not applicableNot yet recruiting90